Maladministration on GMOs by the EU Commission Distorting Markets
Brussels, 8 April 2016 – EuropaBio is highly concerned that the EU Commission continues the same practices of maladministration which were criticised by the European Ombudsman as recently as January 2016.
Brussels, 8 April 2016 – EuropaBio is highly concerned that the EU Commission continues the same practices of maladministration which were criticised by the European Ombudsman as recently as January 2016. Three genetically modified soya bean products have been pending in the EU product approval system since 2011 and 2012 respectively, including nearly three months and counting for the last step of authorisation by the Commission.
The European Ombudsman decided in January: “In circumstances where, presumably, the substantive work on the individual case had already been done in advance of engaging with the Standing Committee and Appeal Committee, it is difficult to see why the Commission would need a further 3.5 months in which to take its decision. Given that a further delay at this stage might have adverse consequences for the complainants, and in the absence of any reasonable explanation for these delays, the Ombudsman finds that these delays by the Commission constituted maladministration.”
Nathalie Moll, EuropaBio Secretary General, urges the Commission to take its responsibility: “We call on the Commission to immediately finalise the adoption of these authorisation proposals at its college meeting of 12th April, in accordance with the existing legal requirements of Regulation 1829/2003 and the EU Charter of Fundamental Rights, so as to avoid any additional undue delays.”
Given we are currently in the sowing season, the Commission’s maladministration regarding these three products is already creating concrete market disruption and material damage.
This content is published by the Parliament Magazine on behalf of our partners.
The EU must 'take right decisions' to support the 'success story' of plant breeding innovation, argues Garlich Von Essen.
Europe's animal health industry is committed, innovative and resilient, explains IFAH's Roxane...
Current EU veterinary medicines review lacks focus on ROI for innovative companies, argues IFAH-Europe's Rick Clayton.